In stent restenosis (ISR) continues to be the main limitation to the percutaneous treatment of coronary artery disease, with 5 to 10% prevalence after new generation DES stenting. Guideline recommendations for this intervention include new DES stenting and the use of drug coated balloons (DCB). Recurrent ISR stenting rate ranges between 10 and 40%, and...
✔️ SOLACI-SBHCI 2023 – Internationl Live Case | Left Main PCI with Dedicated DES Guided by HD Imaging ✔️ Site: LEIPZIG HEART CENTER – LEIPZIG, GERMANY ✔️ August 3, 2023, Copacabana Room, Windsor Oceánico
In-stent restenosis (ISR) remains the primary limitation of percutaneous treatment for coronary artery disease. The strategy to address this limitation involves the use of drug-eluting stents (DES) or drug-coated balloons (DCB), both of which have proven to be effective and safe therapeutic alternatives. Despite current recommendations, treating ISR continues to be a challenge, and clinical...
During the SOLACI-SBHCI 2023 Congress, a special session was held to honor the great figures of interventional cardiology in Brazil and Latin America, whose leadership led to the greatness of the Latin American Society of Interventional Cardiology and the Brazilian Society of Hemodynamics and Interventional Cardiology. At the beginning of the session, Dr. Ricardo Costa...
Score to predict the risk of repeat PCI in DES restenosis. With the use of drug eluting stents (DES) instent restenosis (ISR) has seen a significant reduction vs. bare metal stents (BMS) restenosis. The main cause of DES failure is ISR. This entity is difficult to manage because of its high recurrence and reintervention risk....
Recent studies have shown that drug-eluting stents with biodegradable polymer and ultrathin struts are safe and effective, including low rates of stent thrombosis. This is why researchers conducted the BIODEGRADE (Biomatrix and Orsiro Drug-Eluting Stents in Angiographic Result in Patients With Coronary Artery Disease) study, which showed the non-inferiority at 18 months of ultrathin biodegradable polymer...
By Dr. Roberto Esporcatte.
Enjoy this master conference given by Dr. Roxana Mehran during the SOLACI-SOCIME 2022 Congress held at Expo Santa Fé, CDMX on August 4, 5 and 6, 2022. Topic: Advances in the design of STENTS in PCI: DIABETES MELLITUS.
Read the most outstanding articles from the second day of the SOLACI-SOCIME 2022 Congress. In this case, consult the presentation by Dr. Aníbal Damonte, entitled “El Desafío de PCI en pacientes con HBR”
Peripheral vascular disease (PVD) has been under-studied and under-recognized in comparison with ischemic heart disease and stroke, despite its well-known impact on quality of life and its associated morbidity and mortality. According to a systematic review, it was estimated that in 2015 about 238 million people globally had PVD. This number is on the rise....